arrow
A

Avner Reshef

barzilai university hospital
H指数:37
被引数:5,464

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

International Guideline on the Diagnosis and Management of Pediatric Patients With Hereditary Angioedema

遗传性血管性水肿儿童患者诊断与管理国际指南

2026-01-300
OAAI
Long-term safety and efficacy of once-daily berotralstat in patients with hereditary angioedema

伯罗特拉斯特每日一次给药在遗传性血管性水肿患者中的长期安全性和有效性

2025-06-070
PREAI
Long-term safety and efficacy of garadacimab for preventing hereditary angioedema attacks: Phase 3 open-label extension study

garadacimab预防遗传性血管性水肿发作的长期安全性和有效性: 3期开放标签扩展研究

2024-10-072
OAAI
Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension study
2024-06-012
PRE
A Core Outcome Set for Efficacy of Acute Treatment of Hereditary Angioedema
2024-06-013
OAAI
Efficacy and safety of recombinant human C1-inhibitor for the treatment of attacks of hereditary angioedema: European open-label extension study

重组人C1-inhibitor治疗遗传性血管性水肿发作的疗效和安全性: 欧洲开放标签扩展研究

2023-11-0151
PREAI
Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
LANCET
IF88.5
2023-04-0145
PRE
Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial
LANCET
IF88.5
2022-03-0146
PRE
The international WAO/EAACI guideline for the management of hereditary angioedema - The 2021 revision and update
2022-03-0153
OAAI
The international WAO/EAACI guideline for the management of hereditary angioedema-The 2021 revision and update
2022-02-03224
OA